How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses. uri icon

Overview

publication date

  • August 28, 2015

Research

keywords

  • Antineoplastic Agents
  • Hematologic Neoplasms
  • Quality of Life
  • Quality-Adjusted Life Years

Identity

PubMed Central ID

  • PMC4600021

Scopus Document Identifier

  • 84943599112

Digital Object Identifier (DOI)

  • 10.1182/blood-2015-07-657478

PubMed ID

  • 26320099

Additional Document Info

volume

  • 126

issue

  • 15